Audit 351508

FY End
2024-06-30
Total Expended
$316.48M
Findings
28
Programs
95
Year: 2024 Accepted: 2025-03-31
Auditor: Kpmg LLP

Organization Exclusion Status:

Checking exclusion status...

Findings

ID Ref Severity Repeat Requirement
547122 2024-002 Significant Deficiency - I
547123 2024-002 Significant Deficiency - I
547124 2024-002 Significant Deficiency - I
547125 2024-002 Significant Deficiency - I
547126 2024-002 Significant Deficiency - I
547127 2024-003 Material Weakness - F
547128 2024-002 Significant Deficiency - I
547129 2024-002 Significant Deficiency - I
547130 2024-002 Significant Deficiency - I
547131 2024-002 Significant Deficiency - I
547132 2024-004 Significant Deficiency - H
547133 2024-002 Significant Deficiency - I
547134 2024-002 Significant Deficiency - I
547135 2024-002 Significant Deficiency - I
1123564 2024-002 Significant Deficiency - I
1123565 2024-002 Significant Deficiency - I
1123566 2024-002 Significant Deficiency - I
1123567 2024-002 Significant Deficiency - I
1123568 2024-002 Significant Deficiency - I
1123569 2024-003 Material Weakness - F
1123570 2024-002 Significant Deficiency - I
1123571 2024-002 Significant Deficiency - I
1123572 2024-002 Significant Deficiency - I
1123573 2024-002 Significant Deficiency - I
1123574 2024-004 Significant Deficiency - H
1123575 2024-002 Significant Deficiency - I
1123576 2024-002 Significant Deficiency - I
1123577 2024-002 Significant Deficiency - I

Programs

ALN Program Spent Major Findings
84.268 Federal Direct Student Loans $106.00M - 0
93.342 Health Professions Student Loans, Including Primary Care Loans and Loans for Disadvantaged Students $6.50M - 0
93.493 Congressional Directives $3.65M Yes 2
93.364 Nursing Student Loans $3.20M - 0
93.211 Telehealth Programs $3.00M Yes 1
93.917 Hiv Care Formula Grants $1.88M - 0
93.264 Nurse Faculty Loan Program (nflp) $1.76M - 0
93.353 21st Century Cures Act - Beau Biden Cancer Moonshot $1.39M Yes 1
84.038 Federal Perkins Loan Program_federal Capital Contributions $1.07M - 0
93.399 Cancer Control $1.02M Yes 1
93.859 Biomedical Research and Research Training $906,659 Yes 0
16.321 Antiterrorism Emergency Reserve $812,159 Yes 0
93.925 Scholarships for Health Professions Students From Disadvantaged Backgrounds $674,996 - 0
93.243 Substance Abuse and Mental Health Services Projects of Regional and National Significance $627,596 - 0
12.910 Research and Technology Development $609,889 Yes 0
93.396 Cancer Biology Research $532,043 Yes 0
93.912 Rural Health Care Services Outreach, Rural Health Network Development and Small Health Care Provider Quality Improvement $522,971 Yes 0
93.870 Maternal, Infant and Early Childhood Home Visiting Grant $510,567 Yes 0
93.884 Primary Care Training and Enhancement $454,076 Yes 0
93.939 Hiv Prevention Activities Non-Governmental Organization Based $447,940 Yes 0
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $340,417 Yes 0
93.846 Arthritis, Musculoskeletal and Skin Diseases Research $329,890 Yes 0
93.121 Oral Diseases and Disorders Research $310,859 Yes 0
93.877 Autism Collaboration, Accountability, Research, Education, and Support $302,524 Yes 0
93.394 Cancer Detection and Diagnosis Research $299,386 Yes 0
97.044 Assistance to Firefighters Grant $277,769 Yes 0
93.165 Grants to States for Loan Repayment $255,545 - 0
66.509 Science to Achieve Results (star) Research Program $223,044 Yes 0
84.063 Federal Pell Grant Program $205,232 - 0
93.059 Training in General, Pediatric, and Public Health Dentistry $203,702 Yes 0
16.582 Crime Victim Assistance/discretionary Grants $200,428 - 0
16.575 Crime Victim Assistance $193,982 - 0
93.867 Vision Research $175,282 Yes 0
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $169,599 Yes 0
93.173 Research Related to Deafness and Communication Disorders $159,166 Yes 0
93.391 Activities to Support State, Tribal, Local and Territorial (stlt) Health Department Response to Public Health Or Healthcare Crises $143,005 - 0
10.555 National School Lunch Program $135,901 - 0
93.879 Medical Library Assistance $131,227 Yes 0
93.838 Lung Diseases Research $114,530 Yes 0
64.U01 Other Federal Assistance $114,060 - 0
93.307 Minority Health and Health Disparities Research $112,831 Yes 0
16.123 Community-Based Violence Prevention Program $110,354 Yes 0
93.398 Cancer Research Manpower $110,060 Yes 0
93.393 Cancer Cause and Prevention Research $86,817 Yes 0
12.420 Military Medical Research and Development $83,874 Yes 0
93.279 Drug Use and Addiction Research Programs $77,229 Yes 0
93.865 Child Health and Human Development Extramural Research $75,270 Yes 0
84.033 Federal Work-Study Program $74,323 - 0
93.823 Public Health Response, Forecasting, and Analytic Capacities Related to Disease Outbreaks, Epidemics, and Pandemics $72,707 Yes 0
93.110 Maternal and Child Health Federal Consolidated Programs $62,439 Yes 0
81.136 Long-Term Surveillance and Maintenance $55,329 - 0
93.273 Alcohol Research Programs $48,491 Yes 0
93.350 National Center for Advancing Translational Sciences $46,830 Yes 0
93.530 Teaching Health Center Graduate Medical Education Payment $43,937 - 0
47.076 Stem Education (formerly Education and Human Resources) $42,833 Yes 0
93.077 Family Smoking Prevention and Tobacco Control Act Regulatory Research $41,838 Yes 0
93.397 Cancer Centers Support Grants $37,919 Yes 0
93.945 Assistance Programs for Chronic Disease Prevention and Control $31,669 Yes 0
93.124 Nurse Anesthetist Traineeship $31,272 - 0
93.516 Public Health Training Centers Program $31,179 Yes 0
93.361 Nursing Research $29,901 Yes 0
93.310 Trans-Nih Research Support $29,405 Yes 0
84.324 Research in Special Education $28,452 - 0
93.866 Aging Research $26,892 Yes 0
93.395 Cancer Treatment Research $25,916 Yes 0
93.765 Pphf-Cdc Partnership: Strengthening Public Health Laboratories $23,818 - 0
93.837 Cardiovascular Diseases Research $23,402 Yes 0
84.007 Federal Supplemental Educational Opportunity Grants $20,761 - 0
93.234 Traumatic Brain Injury State Demonstration Grant Program $18,990 Yes 0
93.855 Allergy and Infectious Diseases Research $18,849 Yes 0
47.075 Social, Behavioral, and Economic Sciences $17,482 Yes 0
93.433 Acl National Institute on Disability, Independent Living, and Rehabilitation Research $14,844 Yes 0
64.RD1 Other Federal Assistance $14,727 Yes 0
93.226 Research on Healthcare Costs, Quality and Outcomes $10,775 Yes 0
93.213 Research and Training in Complementary and Integrative Health $7,279 Yes 0
93.130 Cooperative Agreements to States/territories for the Coordination and Development of Primary Care Offices $7,184 - 0
43.003 Exploration $4,786 Yes 0
45.024 Promotion of the Arts Grants to Organizations and Individuals $3,728 Yes 0
93.113 Environmental Health $2,574 Yes 0
93.191 Graduate Psychology Education $2,060 Yes 0
93.236 Grants to States to Support Oral Health Workforce Activities $1,535 Yes 0
43.008 Office of Stem Engagement (ostem) $1,476 Yes 0
93.155 Rural Health Research Centers $1,260 Yes 0
93.839 Blood Diseases and Resources Research $794 Yes 0
93.788 Opioid Str $306 - 0
93.959 Block Grants for Prevention and Treatment of Substance Abuse $190 Yes 0
93.732 Mental and Behavioral Health Education and Training Grants $73 - 0
93.421 Strengthening Public Health Systems and Services Through National Partnerships to Improve and Protect the Nation’s Health $54 - 0
93.RD1 Test for Suppression Effects of Advanced Energy $-35 Yes 0
93.103 Food and Drug Administration Research $-5,256 Yes 0
93.242 Mental Health Research Grants $-5,662 Yes 0
93.107 Area Health Education Centers $-7,102 - 0
93.247 Advanced Nursing Education Workforce Grant Program $-7,616 - 0
47.083 Integrative Activities $-8,359 Yes 0
93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health $-19,326 Yes 0

Contacts

Name Title Type
NHV3GTWSALA7 Susan Edwards Auditee
8437922853 Alison Upton Auditor
No contacts on file

Notes to SEFA

Title: Basis of Presentation Accounting Policies: The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of the Medical University of South Carolina (the University) and is presented on the accrual basis of accounting. The information in the Schedule is presented in accordance with the requirements of Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards at Title 2 U.S. Code of Federal Regulation Part 200 (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in or used in the preparation of the basic financial statements.Expenditures for student financial aid programs include the federal share of students’ Federal Supplemental Educational Opportunity Grant (FSEOG) program grants and Federal Work-Study (FWS) Program earnings, certain other federal financial aid for students, and administrative cost allowances, where applicable. Federal Pell grant awards are recognized as agency transactions and are not recorded as expenditures in the financial statements. Expenditures for federal research and development programs are determined using the cost accounting principles and procedures set forth in OMB Circular A-21, Cost Principles for Educational Institutions, or the cost principles contained in Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement. De Minimis Rate Used: N Rate Explanation: The University did not elect to use the 10% de minimis indirect cost rate, as discussed in Uniform Guidance Section 200.414. The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of the Medical University of South Carolina (the University) and is presented on the accrual basis of accounting. The information in the Schedule is presented in accordance with the requirements of Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards at Title 2 U.S. Code of Federal Regulation Part 200 (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in or used in the preparation of the basic financial statements.
Title: Summary of Significant Accounting Policies for Federal Award Expenditures Accounting Policies: The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of the Medical University of South Carolina (the University) and is presented on the accrual basis of accounting. The information in the Schedule is presented in accordance with the requirements of Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards at Title 2 U.S. Code of Federal Regulation Part 200 (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in or used in the preparation of the basic financial statements.Expenditures for student financial aid programs include the federal share of students’ Federal Supplemental Educational Opportunity Grant (FSEOG) program grants and Federal Work-Study (FWS) Program earnings, certain other federal financial aid for students, and administrative cost allowances, where applicable. Federal Pell grant awards are recognized as agency transactions and are not recorded as expenditures in the financial statements. Expenditures for federal research and development programs are determined using the cost accounting principles and procedures set forth in OMB Circular A-21, Cost Principles for Educational Institutions, or the cost principles contained in Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement. De Minimis Rate Used: N Rate Explanation: The University did not elect to use the 10% de minimis indirect cost rate, as discussed in Uniform Guidance Section 200.414. Expenditures for student financial aid programs include the federal share of students’ Federal Supplemental Educational Opportunity Grant (FSEOG) program grants and Federal Work-Study (FWS) Program earnings, certain other federal financial aid for students, and administrative cost allowances, where applicable. Federal Pell grant awards are recognized as agency transactions and are not recorded as expenditures in the financial statements. Expenditures for federal research and development programs are determined using the cost accounting principles and procedures set forth in OMB Circular A-21, Cost Principles for Educational Institutions, or the cost principles contained in Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement.
Title: Noncash Assistance Accounting Policies: The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of the Medical University of South Carolina (the University) and is presented on the accrual basis of accounting. The information in the Schedule is presented in accordance with the requirements of Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards at Title 2 U.S. Code of Federal Regulation Part 200 (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in or used in the preparation of the basic financial statements.Expenditures for student financial aid programs include the federal share of students’ Federal Supplemental Educational Opportunity Grant (FSEOG) program grants and Federal Work-Study (FWS) Program earnings, certain other federal financial aid for students, and administrative cost allowances, where applicable. Federal Pell grant awards are recognized as agency transactions and are not recorded as expenditures in the financial statements. Expenditures for federal research and development programs are determined using the cost accounting principles and procedures set forth in OMB Circular A-21, Cost Principles for Educational Institutions, or the cost principles contained in Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement. De Minimis Rate Used: N Rate Explanation: The University did not elect to use the 10% de minimis indirect cost rate, as discussed in Uniform Guidance Section 200.414. Most federal financial assistance is in the form of cash awards. However, there are a number of federal programs that do not involve cash transactions with the University. These noncash transactions in which the University obtains other assistance are the Federal Direct Student Loan Program, which includes the Federal Direct Stafford Student Loan program (subsidized and unsubsidized) and the Federal Direct Parent Loans for Undergraduate Students (PLUS). The loans are as follows for the various student loan programs: ALN Amount Federal Direct Student Loan Program – Student loans: 84.268 $ 106,001,697 Direct Stafford Loan Program 673,469 Direct Unsubsidized Stafford Loan Program 58,892,693 Federal Direct PLUS Loan Program 402,673 Federal Direct Graduate PLUS Loan Program 46,032,862 Total Federal Direct Student Loan Program $ 106,001,697The Federal Perkins Loan, the Health Professions Student Loan (HPSL), the Nurse Faculty Loan Program (NFLP), and the Nursing Student Loan (NSL) programs are administered directly by the University, and balances and transactions relating to these programs are included in the University’s basic financial statements. The balance of loans outstanding under the Federal Perkins, HPSL, NFLP, and NSL programs was $680,503, $5,914,778, $1,528,647, and $2,770,176, respectively, as of June 30, 2024. The University is responsible only for the performance of certain administrative duties with respect to the guaranteed student loan programs, and accordingly, these loans are not included in its financial statements. It is not practicable to determine the balance of loans outstanding to students and former students of the University under these programs as of June 30, 2024.
Title: Matching Accounting Policies: The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of the Medical University of South Carolina (the University) and is presented on the accrual basis of accounting. The information in the Schedule is presented in accordance with the requirements of Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards at Title 2 U.S. Code of Federal Regulation Part 200 (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in or used in the preparation of the basic financial statements.Expenditures for student financial aid programs include the federal share of students’ Federal Supplemental Educational Opportunity Grant (FSEOG) program grants and Federal Work-Study (FWS) Program earnings, certain other federal financial aid for students, and administrative cost allowances, where applicable. Federal Pell grant awards are recognized as agency transactions and are not recorded as expenditures in the financial statements. Expenditures for federal research and development programs are determined using the cost accounting principles and procedures set forth in OMB Circular A-21, Cost Principles for Educational Institutions, or the cost principles contained in Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement. De Minimis Rate Used: N Rate Explanation: The University did not elect to use the 10% de minimis indirect cost rate, as discussed in Uniform Guidance Section 200.414. Under the FWS program, the University matched $74,323 in total compensation for the year ended June 30, 2024 in addition to the federal share of expenditures in the accompanying schedule of expenditures of federal awards. Under the FSEOG program, the University matched $20,761 in funds awarded to students for the year ended June 30, 2024 in addition to the federal expenditures in the accompanying schedule of expenditures of federal awards.
Title: Indirect Cost Rate Accounting Policies: The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of the Medical University of South Carolina (the University) and is presented on the accrual basis of accounting. The information in the Schedule is presented in accordance with the requirements of Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards at Title 2 U.S. Code of Federal Regulation Part 200 (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in or used in the preparation of the basic financial statements.Expenditures for student financial aid programs include the federal share of students’ Federal Supplemental Educational Opportunity Grant (FSEOG) program grants and Federal Work-Study (FWS) Program earnings, certain other federal financial aid for students, and administrative cost allowances, where applicable. Federal Pell grant awards are recognized as agency transactions and are not recorded as expenditures in the financial statements. Expenditures for federal research and development programs are determined using the cost accounting principles and procedures set forth in OMB Circular A-21, Cost Principles for Educational Institutions, or the cost principles contained in Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement. De Minimis Rate Used: N Rate Explanation: The University did not elect to use the 10% de minimis indirect cost rate, as discussed in Uniform Guidance Section 200.414. The University did not elect to use the 10% de minimis indirect cost rate, as discussed in Uniform Guidance Section 200.414.

Finding Details

Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Equipment Property Management Federal Program: Congressional Directives (ALN 93.493) Federal Agency: Department of Health and Human Services Federal Award Number: 1CE1HS52890-01-00 Federal Award Year: September 30, 2023 through June 30, 2024 Criteria or Requirement Per 2 CFR section 200.313, property records must be maintained that include a description of the property, a serial number or other identification number, the source of funding for the property (including the federal award identification number), who holds title, the acquisition date, cost of the property, percentage of federal participation in the project costs for the federal award under which the property was acquired, the location, use and condition of the property, and any ultimate disposition data including the date of disposal and sales price of the property. Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 4 out of 14 purchase transactions or 17 out of 20 individual assets, equipment exceeding the capitalization threshold per 2 CFR section 200.1 was not capitalized. Therefore, a property record did not exist for federally funded equipment purchased in the amount of $1,758,365. The total program expenditures were $3,652,263 for which $2,776,884 were capital equipment purchases and $875,379 were non-capital purchases. For the equipment that was capitalized and a property record was established, the property record did not properly identify the asset as federally funded. Cause and Potential Effect The University's internal controls for determining and documenting whether an equipment acquisition was a capital asset for which a property record should be created in the system with the required was not operating effectively. Accordingly, the University acquired federally funded equipment and a property record was not created. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample.Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over equipment purchases to ensure that a property record is created within the system containing the required information for all federally funded equipment. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Period of Performance Federal Program: Research and Development Cluster - Arthritis, Musculoskeletal and Skin Diseases Research (ALN 93.846) Federal Agency: Department of Health and Human Services Federal Award Number: R01AR071410 Federal Award Year: July 1, 2023 through June 30, 2024 Criteria or Requirement Per 2 CFR section 200.403(h), a non-federal entity may charge only allowable costs incurred during the approved budget period of a federal award’s period of performance and any costs incurred before the federal awarding agency or pass-through entity made the federal award that were authorized by the federal awarding agency or pass-through entity. Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 1 of 40 transactions sampled for period of performance, purchase incurred after the period of performance was charged to the grant which is not allowable under the grant award or cost principles. Cause and Potential Effect The University's internal controls for determining a purchase is within the federal award’s period of performance was not operating effectively. Accordingly, the University has requested reimbursement for purchases incurred after the period of performance of the federal award. Questioned Cost There are known questioned costs of $16,017. The aggregated total sample for the 40 period of performance transactions was $2,132,385. The total population for research and development cluster expenditures aggregated $184,508,852. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample.Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over purchases to ensure the purchases are incurred within the federal award’s period of performance and if incurred subsequent to the federal award’s period of performance, are not charged to the federal agency. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Equipment Property Management Federal Program: Congressional Directives (ALN 93.493) Federal Agency: Department of Health and Human Services Federal Award Number: 1CE1HS52890-01-00 Federal Award Year: September 30, 2023 through June 30, 2024 Criteria or Requirement Per 2 CFR section 200.313, property records must be maintained that include a description of the property, a serial number or other identification number, the source of funding for the property (including the federal award identification number), who holds title, the acquisition date, cost of the property, percentage of federal participation in the project costs for the federal award under which the property was acquired, the location, use and condition of the property, and any ultimate disposition data including the date of disposal and sales price of the property. Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 4 out of 14 purchase transactions or 17 out of 20 individual assets, equipment exceeding the capitalization threshold per 2 CFR section 200.1 was not capitalized. Therefore, a property record did not exist for federally funded equipment purchased in the amount of $1,758,365. The total program expenditures were $3,652,263 for which $2,776,884 were capital equipment purchases and $875,379 were non-capital purchases. For the equipment that was capitalized and a property record was established, the property record did not properly identify the asset as federally funded. Cause and Potential Effect The University's internal controls for determining and documenting whether an equipment acquisition was a capital asset for which a property record should be created in the system with the required was not operating effectively. Accordingly, the University acquired federally funded equipment and a property record was not created. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample.Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over equipment purchases to ensure that a property record is created within the system containing the required information for all federally funded equipment. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Period of Performance Federal Program: Research and Development Cluster - Arthritis, Musculoskeletal and Skin Diseases Research (ALN 93.846) Federal Agency: Department of Health and Human Services Federal Award Number: R01AR071410 Federal Award Year: July 1, 2023 through June 30, 2024 Criteria or Requirement Per 2 CFR section 200.403(h), a non-federal entity may charge only allowable costs incurred during the approved budget period of a federal award’s period of performance and any costs incurred before the federal awarding agency or pass-through entity made the federal award that were authorized by the federal awarding agency or pass-through entity. Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 1 of 40 transactions sampled for period of performance, purchase incurred after the period of performance was charged to the grant which is not allowable under the grant award or cost principles. Cause and Potential Effect The University's internal controls for determining a purchase is within the federal award’s period of performance was not operating effectively. Accordingly, the University has requested reimbursement for purchases incurred after the period of performance of the federal award. Questioned Cost There are known questioned costs of $16,017. The aggregated total sample for the 40 period of performance transactions was $2,132,385. The total population for research and development cluster expenditures aggregated $184,508,852. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample.Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over purchases to ensure the purchases are incurred within the federal award’s period of performance and if incurred subsequent to the federal award’s period of performance, are not charged to the federal agency. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.
Finding No. 2024-002 Procurement – Suspension and Debarment Federal Program, Federal Agency, Federal Award Number, Federal Award Year Federal program ALN Federal Agency Federal Award Number Federal Award Year R&D cluster 93.211 Department of Health and Human Services 2U66RH31458-04-00 July 1, 2023 to June 30, 2024 R&D cluster 93.243 Department of Health and Human Services 1H79SM085079-01 July 1, 2023 to June 30, 2024 R&D cluster 93.279 Department of Health and Human Services 5126934/1R01DA055523-01A1; U10DA013727-21 July 1, 2023 to June 30, 2024 R&D cluster 93.310 Department of Health and Human Services 1UG3OD035543-01,02 July 1, 2023 to June 30, 2024 R&D cluster 93.353 Department of Health and Human Services 3U01CA232491-02S1 July 1, 2023 to June 30, 2024 R&D cluster 93.395 Department of Health and Human Services 2R01CA181664-07A1 July 1, 2023 to June 30, 2024 R&D cluster 93.399 Department of Health and Human Services 5UG1CA189848-08; 7R01CA232888-05 July 1, 2023 to June 30, 2024 R&D cluster 93.847 Department of Health and Human Services 5U01DK104833-06 July 1, 2023 to June 30, 2024 R&D cluster 93.853 Department of Health and Human Services 1OT2NS129366-01 July 1, 2023 to June 30, 2024 Congressional Directives 93.493 Department of Health and Human Services CE1H552890 September 30, 2023 to June 30, 2024 Criteria or Requirement Per 2 CFR section 180.300, when a non-federal entity enters into a covered transaction with an entity at a lower tier, the non-federal entity must verify that the entity is not suspended or debarred or otherwise excluded from participating in the transaction.Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition and Context For 11 out of 40 R&D procurement transactions and 9 out of 13 Congressional Directive procurement transactions, the University could not provide documentation to support that they checked suspension and debarment on a timely basis. The documentation provided evidenced that the University checked that the vendor was not suspended or debarred at some point after the covered transaction occurred. Cause and Potential Effect The University’s internal controls for determining and documenting whether a vendor was not suspended or debarred prior to entering into the covered procurement transaction with that vendor was not operating effectively. Accordingly, the University could have entered into a covered procurement transaction with a suspended or debarred vendor. Questioned Cost There were no questioned costs associated with the finding. Statistically Valid Sample The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding is a Repeat of a Finding in the Immediately Prior Audit No. Recommendation We recommend the University enhance the precision of the controls over suspension and debarment to ensure that, prior to entering into each covered procurement transaction, the University has checked to determine that the vendor is not suspended or debarred, and the results are documented. View of Responsible Officials Management of the University takes no exception to this reported finding. We have implemented the remedial actions as outlined in our Corrective Action Plan.